We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+21.02%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$161M
AUM Growth
-$8.98M
Cap. Flow
-$4.31M
Cap. Flow %
-2.68%
Top 10 Hldgs %
86.68%
Holding
32
New
3
Increased
7
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$13.4M
2
IMA
ImageneBio Inc
IMA
+$4.82M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$3.18M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$2.82M
5
TIL icon
Instil Bio
TIL
+$1.98M

Top Sells

Rank Stock Value
1
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$16.1M
2
TECX
Tectonic Therapeutic
TECX
+$6.42M
3
OKUR
OnKure Therapeutics
OKUR
+$5.88M
4
LENZ
LENZ Therapeutics
LENZ
+$1.55M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$1.07M

Sector Composition

Rank Sector Weight
1 Healthcare 82.88%
2 Technology 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIL icon
26
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$47.1B
– –
-175,000
Closed -$16.1M
CALC icon
27
CalciMedica
CALC
$11.9M
– –
-153,887
Closed -$682K
FBRX icon
28
Forte Biosciences
FBRX
$1.57B
– –
-70,468
Closed -$394K
VNDA icon
29
Vanda Pharmaceuticals
VNDA
$298M
– –
-228,500
Closed -$1.07M
TECX
30
Tectonic Therapeutic
TECX
$553M
– –
-211,752
Closed -$6.42M
OKUR
31
OnKure Therapeutics
OKUR
$161M
– –
-345,740
Closed -$5.88M
TLIS
32
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
– –
-248,702
Closed -$460K
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $156M AUM 19.16% 1-Year Est. Return
GSWA
Good Steward Wealth Advisors Clarksville, Tennessee $156M AUM 13.06% 1-Year Est. Return
SPM
Summit Portfolio Management Las Vegas, Nevada $155M AUM

BML Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, BML Capital Management held 32 positions worth $161M, down 5.3% from $170M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

BML Capital Management's Q4 2024 filing shows 3 new, 7 increased, 5 reduced and 7 closed positions. Its largest new stake was ESSA Pharma: 4,221,546 shares worth $7.56M. The largest sale was State Street SPDR Bloomberg 1-3 Month T-Bill ETF, an estimated $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 74% a quarter earlier, followed by Technology.

  • BML Capital Management's largest Q4 2024 buy was ESSA Pharma: 4,221,546 shares worth $7.56M.
  • BML Capital Management added most to ImageneBio Inc in Q4 2024, an estimated $4.82M increase.
  • BML Capital Management's biggest Q4 2024 reduction was LENZ Therapeutics, cutting an estimated $1.55M.
  • BML Capital Management fully exited State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q4 2024, selling an estimated $16.1M.
  • BML Capital Management's ten largest holdings make up 87% of its $161M portfolio in Q4 2024.
  • BML Capital Management opened 3 new positions and closed 7 in Q4 2024.
  • BML Capital Management's portfolio value fell 5.3% quarter-over-quarter to $161M.

Based on BML Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.